Cancer Stem Cells Market Size, Share, and Trends 2025 to 2034

Cancer Stem Cells Market Size and Growth 2025 to 2034

The global cancer stem cells market size was estimated at USD 2.14 billion in 2024 and is predicted to increase from USD 2.40 billion in 2025 to approximately USD 6.60 billion by 2034, expanding at a CAGR of 11.92% from 2025 to 2034. The rising prevalence of cancer cases all around the world and the rising investment in the development of cancer treatment are driving the growth of the cancer stem cells market.

Cancer Stem Cells Market Key Takeaways

• North America dominated the cancer stem cells market share of 44% in 2024.
• Asia Pacific is expected to witness the fastest rate of expansion during the forecast period.
• By type, the breast cancer segment dominated the market in 2024.
• By type, the bladder segment is expected to increase its market growth during the forecast period.
• By application, the stem cell-based cancer therapy segment had the highest market share in 2024.
• By application, the targeted cancerous stem-cell cancer therapy segment is observed to grow at a significant rate during the forecast period.

U.S. Cancer Stem Cells Market Size and Growth 2025 To 2034

The U.S. cancer stem cells market size reached USD 660 million in 2024 and is anticipated to reach around USD 2,070 million by 2034, poised to grow at a CAGR of 12.11% from 2025 to 2034.

North America led the global market with the highest market share of 44% in 2024. The growth of the market in the region is increasing due to the well-established healthcare sector and developed economies like the United States and Canada investing in the development of treatment and medication for various chronic diseases. The increasing presence of the major pharmaceutical companies and research centers is also boosting the growth of the market.

The technologically advanced healthcare infrastructure and the biomedical research centers are proactively researching numerous types of cancer treatment for effective results and innovations. All these factors are collectively contributing to the growth of the cancer stem cells market across the region.

• In October 2022, a U.S.-based biotechnology company, ProMab Biotechnologies, Inc., developed a novel cutting-edge platform to assist researchers in engineering chimeric antigen receptor (CAR)-expressing Natural Killer (NK) cells with CAR mRNA transcription or lipid nanoparticle (LNP) particle transfection as a gene delivery option.

Asia Pacific is expected to witness the fastest rate of expansion in the market during the forecast period. The growth of the market in the region is expected to be boosted due to the rising population and the increasing number of cancer cases in women, the geriatric population, etc.

The growing penetration of cancer cases is resulting in a higher demand for efficient and effective treatment, leading to a higher demand for the market. Furthermore, rising investments in research and development activities and government initiatives for battling against the rising cancer cases are driving the growth of the cancer stem cells market across the region.

Market Overview

Cancer stem cells are the major factor responsible for the development of cancer tumors. It is the subpopulation of the cells found in the tumorigenic tumor. Cancer stem cells have properties like self-renewal and differentiation into various cell types. It produces or regenerates itself in the human body and sustains cancer in the body. It is responsible for the growth and metastasis of cancer.

There are different types of cancer are identified in the human body, such as breast, brain, colon, pancreatic, ovarian, and prostate tumors. In stem cell therapy, stem cells are given to cancer-affected people to replace cells that have been destroyed or eliminated. In cancer-affected people, it is used for regaining the body’s ability to produce stem cells after the treatment. The increasing prevalence of cancer cases due to the changing lifestyle, urbanization, and habits are driving the growth of the cancer stem cells market.

Cancer Stem Cells Market Growth Factors

• The increasing prevalence of chronic disease cancer due to changing lifestyle preferences and environmental conditions is driving the growth of the cancer stem cells market.
• The increase in population and the geriatric population tends to have higher chances of getting diseases like cancer, which drives the demand for cancer stem cells for therapy for eliminating tumors.
• The rising research and development activities for the development of medication for the treatment of cancer and the rising demand for the effective and safer treatment that is used for eliminating the cancer cells from the body with minimal risk of relapse are driving the demand for the cancer stem cells market.
• The rising advancement in cancer drugs and treatment and increasing investments by the private and public sectors for the development of cancer drugs are accelerating the growth of the market. 
• Rising market competition, increasing investments, and strategic collaboration between the market players are contributing to the growth of the cancer stem cells market during the forecast period.

Market Scope

Market Dynamics

Driver

The rising prevalence of cancer cases

The global surge in cancer cases due to the various regions driving the efficient treatment of the disease is driving the demand for the market. The cancer stem cells are one of the most important parts of the treatment of cancer in the initial state. Cancer stem cell therapy targets specific cancer cells and aims to eliminate the chances of cancer coming post-chemotherapy, surgery, or radiation therapy. Cancer stem cell therapy has intricate processes like genetic modulation, cell isolation, and personalized treatment planning. Thus, all these factors collectively contribute to the growth of the cancer stem cells market.

Restraint

Higher cost

The development of cancer stem cell therapy requires extensive research, clinical trials, and preclinical investigations, which requires a significant amount of time and financial investment, which results in a higher cost of the treatment. The increased expenditure during the clinical and preclinical phases directly corresponds to a higher retail price of the drug on approval. The high price associated with cancer treatment restrains the growth of the cancer stem cells market.

Opportunity

Increasing investment and research and development activities

The rising cases of cancer lead to a higher demand for research-based activities in the sector. The increasing demand for treatment and medication due to the increasing types of cancer cases, such as leukemia, lymphoma, and osteopetrosis, are driving the demand for cancer stem cell therapy for the treatment. The extensive research and development activities for the development of cancer treatment and medications and the rising investments by the major pharmaceutical industry and the government bodies for the development of research centers and reducing the number of cancer diseases are collectively contributing to the growth of the cancer stem cells market.

• In January 2023, First Light Acquisition Group and Calidi Biotherapeutics, Inc. announced their merger to create a clinical-stage biotechnology company to develop oncolytic virotherapy using a stem cell-based cancer treatment delivery platform.

Type Insights

The breast cancer segment dominated the cancer stem cells market in 2024. The growth of the segment is attributed to the changing lifestyle preferences of women, which are driving the growth of the segment in the market. Breast cancer is the most commonly seen cancer in women due to various factors such as genetics, excessive fat consumption, exposure to chemicals, alcohol consumption, increasing age, mammographic density, reproductive variables, etc. are some of the considered potential risks for breast cancer in women.

Increasing urbanization and industrialization, changing diets, and reduced physical activities are all contributing to the growth of breast cancer in women. Breast cancer stem cells could be targeted via immunotherapy like adoptive T-cell transfer or dendritic cell (DC)-based therapies which are used in the treatment regimes.

During the forecast period, the bladder cancer segment is expected to increase its growth in the cancer stem cells market. The growth of the segment is attributed to the rising number of bladder cancer cases worldwide, and it is considered the ninth most common disease in the world. The bladder cancer is a malignant development of the aberrant cells. Smoking is the major cause of bladder cancer. It is the most prevalent genitourinary cancer, which is responsible for causing 150,000 deaths every year. There are different treatments for bladder cancer, including open surgery, endoscopic, chemotherapy, immunotherapy, and radiotherapy, which are used for the treatment of this cancer.

Application Insights

The stem cell-based cancer therapy segment dominated the cancer stem cells market in 2024. The growth of the segment is attributed to the higher effectiveness of the treatment as compared to the other procedures that are driving the growth of the cancer stem cells market. Traditional therapies such as chemotherapeutics cannot eliminate the metastatic cancer cells, and there is a higher chance of recurrence of cancer cells. Stem-cell cancer therapy is gaining popularity as the most promising treatment for cancer and eliminating cancer cells.

The therapy is used as a nanoparticle and viral carrier for enhancing the primary therapeutics and reducing the side effects of the treatment. Stem cell therapy is the most effective cancer treatment procedure with unique biological actions, including directional migration, self-renewal, differentiation, and effects on the other cells, which are used as generative medicines, drug targeting, therapeutics carriers, and generation of immune cells.

• In January 2022, U.S.-based next-generation stem cell therapy research and development company Gamida-Cell Ltd. is rolling out a biologics license application (BLA) submission for omidubicel. Omidubicel is a clinically developed off-the-shelf bone marrow stem cell transplant for patients detected with blood cancers.

The targeted cancerous stem-cell cancer therapy segment is expected to grow at a significant rate in the cancer stem cells market during the projected period. Cancer stem cells are the major cause of the recurrence of cancer cells and metastasis. Recent advancements in immunotherapies have shown some promising results in cancer treatment that apply to target cancer stem cells. The cancer stem cells express the immune markers and limit the distinctive immune properties that can be implemented in immunotherapies to target cancer stem cells of the tumor microenvironment.

• In May 2022, Gilead and Dragonfly announced their research collaboration to advance natural killer cell engagers in oncology. Under this agreement, Gilead received a worldwide license from Dragonfly for their 5T4 targeting immunotherapy program DF7001.

Cancer Stem Cells Market Companies

• Lineage Cell Therapeutics, Inc.
• FUJIFILM Irvine Scientific.
• Thermo Fisher Scientific Inc.
• Merck KGaA
• MacroGenics, Inc.
• Miltenyi Biotec
• AbbVie Inc.
• STEMCELL Technologies Inc.
• Bionomics

Recent Developments

• In February 2024, Thumbay University Hospital launched the Cancer Center at Thumbay University in Al Jurf, Ajman. The fully equipped center will be active by the end of February 2024. The rising demand for cancer treatment and screening in the Northern Emirates resulted in the launch of these centers. The cancer center will offer affordable cancer care focusing on multidisciplinary treatment.
• In February 2024, the most prevalent area of development in cancer treatment was NexCAR19, India’s first solely developed and launched CAR-T therapy which is given to patients who are suffering from blood cancer and is now available commercially.
• In February 2024, Glenmark Pharma, in collaboration with Ichnos Science, announced the Ichnos Glenmark Innovation (IGI) to increase the drug delivery in cancer treatment.
• In February 2024, a global innovation-driven healthcare organization, “Zydus Lifesciences Ltd.” launched the Relugolix under the name of Rexigo™. It is the first oral therapy for patients having testosterone suppression and the advanced prostate cancer in India.
• In February 2024, Delfi Diagnostics came into a strategic partnership with Immunocore and announced the launch of a new cancer monitoring test that searches blood for broken pieces of tumor DNA.
• In February 2024, the Royal Surrey NHS Foundation Trust in the United Kingdom announced the start of the clinical trial for the early-stage bowled cancer vaccination for patients from Australia and the United Kingdom.

Segments Covered in the Report

By Type

• Breast
• Bladder
• Blood
• Lung
• Brain
• Colorectal
• Pancreatic
• Liver

By Applications

• Stem Cell-based Cancer Therapy
• Targeted Cancerous Stem Cells

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa